CYP19A1 and breast cancer: For example, 2 randomized controlled trials on the compliance of patients to anastrozole in a therapy program, published by Hadji et al [66], and the influence of a patient information program on adherence and persistence to an aromatase inhibitor in breast cancer treatment, published by Ziller et al [35], were reported in the same 5 systematic reviews [2,7,12,23,25].